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mortality. Imagine too that in 
industrialised countries around a third 
of people are affected by this condition, 
with one person in 12 affected 
severely, and that these proportions 
are increasing. Income, education, sex, 
and ethnicity are not protective, and 
the condition is contagious. The effects 
of the condition are not attributable to 
some peculiarity of the character of a 
subset of individuals, they are a result of 
the condition affecting ordinary people. 
Such a condition exists—loneliness.1–3 
Loneliness is often stigmatised, 
trivialised, or ignored, but—with the 
rapidly growing number of older 
adults in industrialised countries, the 
increased likelihood of premature 
mortality, and the deleterious effects of 
loneliness that have been identified in 
animal models and human longitudinal 
investigations—loneliness is emerging 
as a public health problem.4 Physicians 
are encountering this condition, but 
most do not have the information 
needed to deal effectively with 
loneliness in their patients. 
Loneliness has been associated with 
objective social isolation, depression, 
introversion, or poor social skills. 
However, studies have shown these 
characterisations are incorrect, and 
that loneliness is a unique condition in 
which an individual perceives himself or 
herself to be socially isolated even when 
among other people. Furthermore, 
human longitudinal studies and 
animal models indicate that the 
deleterious effects of loneliness are 
not attributable to some peculiarity 
of individuals who are lonely, instead 
they are due to the effects of loneliness 
on ordinary people.1,5,6 Quick and valid 
measures exist that can diagnose if 
a patient has abnormally high levels 
of loneliness,7 and although so­called 
common sense treatments (eg, social 
skills training, and provisions for social 
support and social contact) have 
proven ineffective,8 the availability of 
community programmes, behavioural 
interventions, and online resources 
is increasing to address the problem 
of loneliness. 
and formulate relevant decisions. 
Science and politics are not familiar 
with joining forces and working 
together, especially in such high­level 
meetings. The Italian G7 Presidency’s 
final communiquè1 shows how this 
collaboration could become possible 
for future meetings too, and how 
a common vision could help to 
sustain and implement appropriate, 
documented, and relevant actions 
and bring measurable results in an 
otherwise purely political framework.
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The growing problem of 
loneliness
Imagine a condition that makes a 
person irritable, depressed, and self­
centred, and is associated with a 
26% increase in the risk of premature 
Loneliness is a public health problem 
that can be largely solved in our 
lifetime but doing so will require the 
full engagement and support of the 
medical community. The physical 
health and mental health of a grow­
ing number of afflicted individuals 
and their families and friends are 
at stake. 
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Influenza vaccination 
and prevention of 
cardiovascular disease 
mortality
Catharine Paules and Kanta Subbarao 
presented in their Seminar (Aug 12, 
2017, p 697) the clinical features, 
therapeutic options, and controversies 
regarding treatment and prevention of 
seasonal influenza infection.1 Although 
they acknowledged that influenza can 
impair different organ systems, little 
attention was given to cardiovascular 
Correspondence
www.thelancet.com   Vol 391   February 3, 2018 427
than in the control group (risk ratio 
0·45, 95% CI 0·26–0·76; p=0·003). 
However, a difference was not observed 
for specific cardiovascular events such 
as acute myocardial infarction, and the 
effectiveness of influenza vaccination 
in primary prevention could not be 
assessed from available data. 
The findings from the Cochrane 
review had moderate bias because 
sample sizes were small and 
cardiovascular events were rare. 
However, the findings support 
influenza vaccination in individuals 
with cardiovascular disease, and are 
reflected in the recommendations 
for influenza vaccination from the 
US Centers for Disease Control and 
Prevention5 and the European Centre 
for Disease Prevention and Control.6 
As stated by Caldeira and colleagues in 
their Correspondence, cardiovascular 
disease is a leading cause of death and 
disability worldwide. Mitigating the 
risk of influenza infection in this high­
risk group through interventions such 
as vaccination could have a substantial 
positive effect on public health. More 
studies are needed to fully understand 
the association between influenza 
infection and cardiovascular events and 
the role of influenza vaccination as a 
prevention strategy.
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consequences. Ischaemic heart disease 
is the leading cause of death worldwide 
and influenza vaccination could reduce 
cardiovascular mortality, particularly in 
patients with coronary heart disease 
for whom cardiovascular mortality 
risk has been reported to be halved by 
influenza vaccination.2 Although this 
conclusion relies on moderate­quality 
randomised placebo­controlled trials 
enrolling a small number of patients 
followed up for up to 1 year,2 the 
possible reduction of cardiovascular 
disease burden in patients with 
coronary heart disease is huge. 
In Europe, which has an influenza 
vaccination coverage of 45·6%,3 
about 30 million individuals have 
ischaemic heart disease,4 and more 
than half a million of these people 
will die from cardiovascular causes 
(figures based on the conservative 
standardised mortality rates of 
individuals aged 65 years and older5). 
Considering that influenza vaccin­
ation is associated with a 24% risk 
reduction of cardiovascular mortality 
in this population (the lower limit of 
95% CI of the estimate),4 an increase of 
coverage to 75% (as recommended by 
the European Council3) would translate 
to about 42 000 potentially avoid­
able cardiovascular deaths in Europe 
among individuals with ischaemic 
heart disease. 
We think that highlighting this 
potential effect on ischaemic heart 
disease is important, since this dis­
ease is responsible for 12·8% of 
total disability­adjusted life­years 
lost in Europe,3 and thus is relevant 
for all stakeholders in health­care 
decision making. 
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Although we briefly mentioned that 
influenza infection could exacerbate 
underlying cardio vascular disease in 
our Seminar,1 we were unable to fully 
expand on this point because of word­
count restrictions. In this regard, an 
epidemiological link between influenza 
and excess deaths associated with 
cardiovascular disease was suggested 
as early as in the 1930s.2 Since then, 
several observational studies have 
supported an association between 
influenza infection, influenza­like 
illness, or respiratory tract infections 
and poor outcomes associated with 
underlying cardiovascular disease. In 
particular, a strong association with 
an increased risk of acute myocardial 
infarction has been reported.2,3 
Therefore, influenza vaccination could 
potentially prevent cardiovascular 
events; a Cochrane review evaluated 
evidence for this intervention.4 The 
systematic analysis revealed that in 
randomised controlled trials that 
examined influenza vaccination as a 
mechanism of secondary prevention, 
significantly fewer cardiovascular 
deaths occurred in the vaccine group 
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